Abstract
Polyvalency in the biological world is defined as the simultaneous binding of multiple ligands to one receptor. Polyvalency can increase the affinity of the polyvalent ligand by 100-1000 fold over the monovalent ligand. Such phenomenon has been employed to design polyvalent toxin inhibitors. Bivalency is a similar approach where two ligands are joined together with a linker to form a homo- or hetero-dimer with an increase in affinity by up to several hundred fold over the monovalent ligand. This review will summarize the recent advancement in designing bivalent inhibitors to be used as antitumour agents. Some dimers (e.g. artemisinin homo-dimer) simply increase the affinity of the monovalent ligands without detailed knowledge of the target. Other dimers are designed with well-characterized targets, for example, jesterone dimer (inhibiting Rel/NF- B) and 3,3-diindolymethane and their derivatives (inhibiting Akt and NF B). Some dimers are designed based on the high definition structure between ligand and target (e.g. benzodiazepine and daunorubicin interacting with DNA). Heterodimers have also been produced by combining either two different antitumor drugs (e.g. cis-platin/acridine or cis-platin/naphthalimide) or combining one antitumor candidate (artemisinin) with a molecule which can increase the efficacy of the former (transferrin receptor). Finally we will discuss the design of bivalent inhibitors of the P-glycoprotein (ABCB1; MDR or P-gp) to overcome the problem of antitumor resistance.
Keywords: Dimer, bivalency, medicinal chemistry, cancer, drug design
Current Pharmaceutical Design
Title: Novel Classes of Dimer Antitumour Drug Candidates
Volume: 15 Issue: 6
Author(s): Larry M.C. Chow and Tak Hang Chan
Affiliation:
Keywords: Dimer, bivalency, medicinal chemistry, cancer, drug design
Abstract: Polyvalency in the biological world is defined as the simultaneous binding of multiple ligands to one receptor. Polyvalency can increase the affinity of the polyvalent ligand by 100-1000 fold over the monovalent ligand. Such phenomenon has been employed to design polyvalent toxin inhibitors. Bivalency is a similar approach where two ligands are joined together with a linker to form a homo- or hetero-dimer with an increase in affinity by up to several hundred fold over the monovalent ligand. This review will summarize the recent advancement in designing bivalent inhibitors to be used as antitumour agents. Some dimers (e.g. artemisinin homo-dimer) simply increase the affinity of the monovalent ligands without detailed knowledge of the target. Other dimers are designed with well-characterized targets, for example, jesterone dimer (inhibiting Rel/NF- B) and 3,3-diindolymethane and their derivatives (inhibiting Akt and NF B). Some dimers are designed based on the high definition structure between ligand and target (e.g. benzodiazepine and daunorubicin interacting with DNA). Heterodimers have also been produced by combining either two different antitumor drugs (e.g. cis-platin/acridine or cis-platin/naphthalimide) or combining one antitumor candidate (artemisinin) with a molecule which can increase the efficacy of the former (transferrin receptor). Finally we will discuss the design of bivalent inhibitors of the P-glycoprotein (ABCB1; MDR or P-gp) to overcome the problem of antitumor resistance.
Export Options
About this article
Cite this article as:
Chow M.C. Larry and Chan Hang Tak, Novel Classes of Dimer Antitumour Drug Candidates, Current Pharmaceutical Design 2009; 15 (6) . https://dx.doi.org/10.2174/138161209787315576
DOI https://dx.doi.org/10.2174/138161209787315576 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
?Revolutionizing Cancer Treatment: Nano-Therapeutics Targeting Tumor Microenvironment?
This thematic issue explores the forefront of cancer treatment, centering on the groundbreaking potential of nano-therapeutics meticulously designed to target the tumor microenvironment. At its core, the issue aims to unravel the latest advancements in nanotechnology, showcasing innovative materials, formulations, and delivery systems that hold promise for redefining cancer therapeutics. ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Plant Defensins and Defensin-Like Peptides - Biological Activities and Biotechnological Applications
Current Pharmaceutical Design Novel Pyrazolo[4, 3-c]Quinolin-3-One Derivatives as PDE5A Inhibitors
Current Topics in Medicinal Chemistry MicroRNAs and Ischemic Heart Disease: Towards a Better Comprehension of Pathogenesis, New Diagnostic Tools and New Therapeutic Targets
Recent Patents on Cardiovascular Drug Discovery Novel Anticoagulants vs Warfarin for Stroke Prevention in Atrial Fibrillation
Cardiovascular & Hematological Disorders-Drug Targets Perioperative Safety of Warfarin Therapy and Reversal
Current Drug Safety Nano Anti-Cancer Drugs: Pros and Cons and Future Perspectives
Current Cancer Drug Targets Gender Differences in Non-Obstructive Coronary Artery Disease
Current Pharmaceutical Design Meet Our Editorial Board Member
Current Vascular Pharmacology Mediators of Low-Grade Chronic Inflammation in Polycystic Ovary Syndrome (PCOS)
Current Pharmaceutical Design Emergence of Lipid-Based Vesicular Carriers as Nanoscale Pharmacotherapy in Rheumatoid Arthritis
Recent Patents on Nanomedicine Beyond Hemostasis: The Role of Platelets in Inflammation, Malignancy and Infection
Cardiovascular & Hematological Disorders-Drug Targets Failing a First Anti-TNF in RA: Does it Imply a Change in Target?
Current Rheumatology Reviews Molecular Targets and Natural Compounds in Drug Development for the Treatment of Inflammatory Pain
Current Drug Targets Structure-Activity Relationships of Flavonoids
Current Organic Chemistry Apoptosis: Potential Therapeutic Targets for New Drug Discovery
Current Medicinal Chemistry Subject Index To Volume 7
Current Pharmaceutical Design The Pamela Study: Old and New Findings
Current Hypertension Reviews Potential of Flavonoids as Anti-inflammatory Agents: Modulation of Pro- Inflammatory Gene Expression and Signal Transduction Pathways
Current Drug Metabolism The Follow-Up of Dietary Treatment of Obesity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Management of Ovarian Cancer in Elderly
Reviews on Recent Clinical Trials